[an error occurred while processing this directive]
中华放射肿瘤学杂志
   2025年4月7日 星期一     首 页 |  期刊介绍  |  编 委 会  |  投稿指南  |  期刊订阅  |  广告合作  |  学术影响  |  收录情况  |  联系我们  |  English
中华放射肿瘤学杂志  2015, Vol. 24 Issue (5): 488-492    DOI: 10.3760/cma.j.issn.1004-4221.2015.05.003
胸部肿瘤 最新目录| 下期目录| 过刊浏览| 高级检索 [an error occurred while processing this directive]|[an error occurred while processing this directive]
广泛期SCLC不同放疗分割方式疗效比较
徐利明, 赵路军, 陈秀丽, 王大权, 陈曦, 王鑫, 巩琳琳, 庞青松, 王军, 袁智勇, 王平
300060 天津,国家肿瘤临床医学研究中心 天津市肿瘤防治重点实验室 天津医科大学肿瘤医院放疗科
Comparison of efficacy of different fractionation schedules in radiotherapy for extensive-stage small cell lung cancer
Xu Liming,Zhao Lujun,Chen Xiuli,Wang Daquan,Chen Xi,Wang Xin,Gong Linlin,Pang Qingsong,Wang Jun,Yuan Zhiyong,Wang Ping
Department of Radiation Oncology,Tianjin Medical University Cancer Institute& Hospital,Key Laboratory of Cancer Prevention and Therapy,National Clinical Research Center for Cancer,Tianjin 300060,China
全文: PDF (0 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      背景资料
摘要 目的 评价不同放疗分割方式与广泛期SCLC患者LC与OS相关性,以明确不同分割方式与预后关系。方法 2010—2015年间初治的110例广泛期SCLC患者接受放化疗,根据放疗剂量分为大分割组31例(30~45 Gy分10~15次)与常规分割组79例(54~60 Gy分27~30次)。90.9%患者临床分期为Ⅳ期。21例患者伴有脑转移。39例行PCI。Kaplan-Meier法计算生存率并Logrank法检验,组间分类数据行χ2检验。结果 全组2年样本量为85例,全组OS、PFS、LC率分别为27.7%、17.5%、38.9%。大分割组与常规分割组的2年OS分别为35%与26%(P=0.886), 2年PFS分别为18%与16%(P=0.560), 2年LC率分别为67%和36%(P=0.159)。PCI与否的2年OS分别为44%和18%(P=0.044)。全组共84例患者治疗失败,其中局部复发11例、远处转移41例、局部复发+远处转移32例。结论 大分割放疗与常规分割放疗疗效相似,但照射时间明显缩短,大分割放疗需要进一步研究。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
徐利明
赵路军
陈秀丽
王大权
陈曦
王鑫
巩琳琳
庞青松
王军
袁智勇
王平
关键词 小细胞肺/放射疗法大分割预后    
Abstract:Objective To evaluate the correlation of different fractionation schedules in radiotherapy with the local control (LC) and overall survival (OS) rates in patients with extensive-stage small cell lung cancer (ES-SCLC), and to figure out the relationship between different fractionation schedules in radiotherapy and the prognosis of ES-SCLC. Methods One hundred and ten patients newly diagnosed with ES-SCLC from February 2010 to March 2015 received chemoradiotherapy. According to the radiation dose, all patients were divided into hypo-fractionation group (30-45 Gy/3 Gy/10-15 f, n=31) and conventional fractionation group (54-60 Gy/1.8-2.0 Gy/27-30 f, n=79). In all patients, 90.9% had stage Ⅳ SCLC;21 patients had brain metastasis;39 patients were treated with prophylactic cranial irradiation (PCI). The Kaplan-Meier method was used to calculate the survival time and log-rank test was used for between-group comparison. Between-group comparison of categorical data was made by χ2 test. Results The number of patients followed-up were 85 at 2-years. In all patients, the 2-year OS, progression-free survival (PFS), and LC rates were 27.7%, 17.5%, and 38.9%, respectively. The hypo-fractionation group had similar prognosis to the conventional fractionation group. There were no significant differences in the 2-year OS, PFS, and LC rates between the two groups (35% vs. 26%, P=0.886;18% vs. 16%, P=0.560;67% vs. 36%, P=0.159). There was also no significant difference in the 2-year OS rate between patients treated with and without PCI (44% vs. 18%, P=0.044). In 84 patients with treatment failure, 11 had local recurrence, 41 had distant metastasis, and 32 had local recurrence plus distant metastasis. Conclusions The hypofractionated radiotherapy has similar efficacy but substantially shortened radiation time compared with conventionally fractionated radiotherapy. The palliative hypofractionated radiotherapy requires further study for ES-SCLC.
Key wordsCarcinoma,small cell lung/radiotherapy    Hypo-fractionation    Prognosis   
    
基金资助:天津市抗癌重大专项公关计划项目(12ZCDZSY15900);天津医科大学博士启动基金(B1320)
通讯作者: 王平,E-mail:wangping@tjmuch.com   
引用本文:   
徐利明,赵路军,陈秀丽等. 广泛期SCLC不同放疗分割方式疗效比较[J]. 中华放射肿瘤学杂志, 2015, 24(5): 488-492.
Xu Liming,Zhao Lujun,Chen Xiuli et al. Comparison of efficacy of different fractionation schedules in radiotherapy for extensive-stage small cell lung cancer[J]. Chinese Journal of Radiation Oncology, 2015, 24(5): 488-492.
链接本文:  
http://journal12.magtechjournal.com/Jweb_fszlx/CN/10.3760/cma.j.issn.1004-4221.2015.05.003     或     http://journal12.magtechjournal.com/Jweb_fszlx/CN/Y2015/V24/I5/488
京公网安备11010502022167号
版权所有 © 2010《中华放射肿瘤学杂志》编辑部
地址:北京朝阳区潘学园南里17号 中国医学科学院肿瘤医院(100021)
电话:010-67700737,87788294 Email: cjron@cmaph.org
本系统由北京玛格泰克科技发展有限公司设计开发 技术支持:Support@magtech.com.cn